PUNE, India, June 21, 2016 /PRNewswire/ --
ReportsnReports.com adds "Irritable Bowel Syndrome - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Irritable Bowel Syndrome with 42 market data tables and 14 figures, spread across 144 pages is available at http://www.reportsnreports.com/reports/594633-irritable-bowel-syndrome-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Irritable Bowel Syndrome Pipeline Review, H1 2016 report include 4D Pharma Plc, A. Menarini Industrie Farmaceutiche Riunite Srl, Alfa Wassermann S.p.A, Allergan Plc, Ardelyx, Inc., Astellas Pharma Inc., CJ HealthCare Corp., Enterome Bioscience SA, Innovate Biopharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Protagonist Therapeutics Inc., RaQualia Pharma Inc., RedHill Biopharma Ltd., SK Biopharmaceuticals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Synergy Pharmaceuticals, Inc., Synthetic Biologics, Inc. and Takeda Pharmaceutical Company Limited.
Drug profiles mentioned in this research report includes ASP-1017, ASP-7147, bedoradrine sulfate, Blautix , CJ-14199, crofelemer DR, DA-6886, DSP-6952 , EB-120, eluxadoline, ibodutant, larazotide acetate, linaclotide, lovastatin, LX-1033, ondansetron hydrochloride CR, ONO-2952, PBF-677, plecanatide, pregabalin, relenopride hydrochloride, rifaximin, RQ-00202730, RQ-00310941, Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine, solabegron hydrochloride, Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea, TAK-480 and tenapanor hydrochloride.
Order a copy of Irritable Bowel Syndrome - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=594633 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome and reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Irritable Bowel Syndrome.
Reasons to buy: Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies; Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage; Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome; Identify potential new clients or partners in the target demographic; Develop strategic initiatives by understanding the focus areas of leading companies; Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics; Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics; Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope as well as modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Another newly published market research report titled on Diphtheria - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Diphtheria. Companies discussed in this research are Beijing Minhai Biotechnology Co., Ltd, Biological E. Limited, Boryung Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, GlaxoSmithKline Plc, Green Cross Corporation, Indian Immunologicals Limited, LG Life Science LTD., Panacea Biotec Limited, Prometheon Pharma, LLC, Sanofi Pasteur SA, Serum Institute of India Limited, Sinovac Biotech Ltd. and Zydus Cadila Healthcare Limited. Diphtheria Pipeline market research report of 89 pages is available at http://www.reportsnreports.com/reports/594634-diphtheria-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+1 888 391 5441